

**Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies**

Hongjian Li<sup>1†</sup>, Kun Peng<sup>1†</sup>, Kai Yang<sup>2</sup>, Wenbo Ma<sup>1</sup>, Shaolong Qi<sup>2</sup>, Xinyang Yu<sup>2</sup>, Jia He<sup>3</sup>, Xin Lin<sup>1,4\*</sup>, and Guocan Yu<sup>2\*</sup>

<sup>1</sup>*Institute for Immunology and School of Medicine, Tsinghua University, Beijing 100084, China.*

<sup>2</sup>*Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, China.*

<sup>3</sup>*School of Pharmaceutical Sciences, Tsinghua University, Beijing 100084, China.*


<sup>4</sup>*Tsinghua-Peking Center for Life Sciences, Beijing 100084, China.*

†These authors contributed equally to the manuscript.


\* Correspondence:

Guocan Yu ([guocanyu@mail.tsinghua.edu.cn](mailto:guocanyu@mail.tsinghua.edu.cn));


Xin Lin ([linxin307@tsinghua.edu.cn](mailto:linxin307@tsinghua.edu.cn))




**Figure 1** **(a)** Agarose gel electrophoresis of D2GFP-coding circRNA precursor (precursor RNA<sup>D2GFP</sup>) and unpurified circRNA (unpurified circRNA<sup>D2GFP</sup>) after RNase R treatment. **(b)** Chromatogram of D2GFP-coding circRNA<sup>D2GFP</sup> via an AKTA purifier system. Protein expression level of circRNA<sup>D2GFP</sup> and linear RNA<sup>D2GFP</sup> in HEK293T cells **(c)** and NIH3T3 cells **(d)** 48 hours after transfection.




**Figure 2** **(a)** The molecular structural formula of the novel ionizable lipid. **(b)**  $^1\text{H}$  NMR spectrum of the compound. **(c)** Chromatogram of OVA (257-264)-luciferase-coding circRNA (circRNA $^{\text{OVA-luc}}$ ) via an AKTA purifier system.




**Figure 3 (a)** Intracellular localization of the LNP and lysosome, characterized by confocal fluorescence microscopic imaging. Red fluorescence dye R300 was encapsulated in LNP and then incubated with mouse embryonic fibroblasts for 0, 2, 4 and 8 hours. Green, Lysotracker 488. Scale bar, 20 $\mu$ m. **(b)** Analysis of the fluorescent value along the selected line (the yellow line) in the merged images.





**Figure 4 (a)** Flow cytometric analysis of D2GFP expression in HEK293T cells. CircRNA<sup>D2GFP</sup> was encapsulated with LNP for transfection. 24 hours after transfection, cells were harvested for flow cytometry assay. **(b)** Cell viability after treatment with increasing doses of the circRNA<sup>D2GFP</sup>-LNP complex. Cells were transfected with increasing RNA doses via LNP. After 24 hours, cell viability was evaluated via CCK-8 assay. **(c)** A workflow of the IRES screening assay in vitro. OVA (257-264)-luciferase-coding circRNA (circRNA<sup>OVA-luc</sup>) with different IRES elements was packaged with LNP and transfected into HEK 293T cells, and luciferase activity was measured 24h after transfection. **(d)** Statistical analysis of luciferase activity in vitro. ns, no significant, \*\* $p < 0.01$ .




**Figure 5 (a-b)** The molecular structural formula of the two FDA-approved ionizable lipids (a, LNP 1; b, LNP 2). Particle size distributions of the circRNA-LNP 1 (c) and circRNA-LNP 2 (d) complex. Zeta potentials of the circRNA-LNP 1 (e) and circRNA-LNP 2 (f) complex. (g) A workflow of the assay in vitro. OVA (257-264)-luciferase-coding circRNA was encapsulated with different LNPs for transfection. 24 hours after transfection, cells were collected for luciferase activity detection assay. (h) Luciferase activity detection in HEK293T cells.




**Figure 6** Comparison of serum cytokine release after RNA-LNP administration in vivo. OVA (257-264)-luciferase-coding circRNA (circRNA<sup>OVA-luc</sup>, 10  $\mu$ g circRNA per mouse), equimolar amount of M1 $\psi$  mRNA (M1 $\psi$  mRNA<sup>OVA-luc</sup>) and PBS were encapsulated with LNP and intramuscularly administrated. 24 hours later, Elisa assay was carried out to detect serum **(a)** IL-6 and **(b)** TNF- $\alpha$  secretion.




**Figure 7 (a)** Average body weight of the mice in OVA-MC38 tumor model. **(b)** Gating strategy of the flow cytometry data for anti-OVA 257-264 peptide (SIINFEKL) T cell detection in Figure 4C.



**Figure 8** Gating strategy of the flow cytometry data for detecting the percentage of IFN- $\gamma$  and TNF- $\alpha$  positive CD8 $^{+}$  T cells in Figure 4E.



**Figure 9 (a)** Average body weight of mice during the experiment of Figure 5A. Gating strategy **(b)** and representative flow dot plots **(c)** for anti-OVA 257-264 peptide (SIINFEKL) T cell detection in Figure 5H.



**Figure 10** Gating strategy of the flow cytometry data for detecting the OT-I ( $CD45.2^+$ ) T cells in all the  $CD8^+$  cells.

Supplementary Table 1

Linear D2GFP RNA templete	taatacgactcaactatagggaaataagagagaaaagaagagaataagagccacgcaccatggta agcaaggcgaggagctttcacgggggtgtgcccacccatctggcagctggacggcgaatggccacaa gttcagcgtccggcgagggcgagggcgatgccacccatcgcaagctgaccctgaagtcatctgcaccacccg caagctgcccgtgcctggccaccctctgaccaccctgacccatcgccgtgcagtgttcagccgtaccccgac cacatgaaggcagcacttcaagtcccatgcccgaaggctacgtccaggagcaccatcttcaggg cgacggcaactacaagacccgcgcgagggtgaagttcgagggcgacaccctgtgaaccgcacgtgaagg gcacgtcaaggaggacggcaacatctggggcacaagctggagtacaactacaacagccacaacgttat catggccgacaaggcagaacggcatcaaggtgaacttcaagatccgcacaacatcgaggacggcagcgtgc agctcgccgaccactaccagcagaacaccccatcgccgacggcccgctgctgcccacaaccactaccta gcacccatcgccctgagcaaagaccccaacgagaagcgcgatcacatggctgtggagttcgaccgg ccgggatactctggcatggacgactgtacaagaagcttagccatggctccggaggtggaggaggcagg atgtggcacgtcgccatgttgcggcaggagacggatggaccgtaccctgcagcctgtgcctctgtcagg atcaatgttaggctgcctctggggcttgccatggccatggcttcctccctgcacctgtaccttggctt tgaataaaggctgagtaggaagt
Circular D2GFP RNA templete	taatacgactcaactataggggagaccctcgaccgtcgattgtccactggtaacaatagatgacttacaactatcg aagggtcgagactcgacggagctaccctaactgtcaagacgaggtaaagagagagatccaattctaaagccaaat aggcagttagcgaagactgtcaagagaatgaaaatccgtgaccctaaacggcgtgtgggtcaagtccctccaccc cacgcccggaaacgcaatagccaaaaacaaaaacaaaaacaaaaaaaacaaaaaaaacaaaaacacatct agattaaaacagcctgtgggtgatcccacccacaggccattggcgctagcactctgttatcaggtagttgtc gcctgtttatacccccccccaactgttaacttagtaacacacaccgtcaacagtcaagcgtggcacaccagcc acgtttgatcaagcacttctgttacccggactgagttcaatagactgctcacgcggtaaggagaaagcgttgc atccggcaactacttcgaaaaaccttagtaacaccgtggaagttgcagagtgttcgctcagactaccctgttag atcaggcgtgatgatcaccgcattccccacgggacccgtggcggtggctgctggcgectgcccattgggaa acccatggacgcttaatacagacatggcgaagagactttagtgcattttatcgttgcacatttgcattttatc gctaatccctaactgcggagcacacaccctcaagccagagggcagttgtcgtaacggcaactctgcagcggaaacc gactacttgggtgtccgtgtttcattttatccctatactggctgttgcataatttgcattttatcgttgcattttatc ggattggccatccggactaataagacttattatcccttgcattttatcgttgcacatttgcattttatcgttgcattttatc attacaatttgcattttatcgttgcattttatcgttgcattttatcgttgcattttatcgttgcattttatcgttgcattttatc

	<p>ctggtcgagctggacggcgacgtaaacggccacaagttcagcgtgtccggcgagggcgagggcgatgccaccta      cggcaagctgaccctgaagttcatctgcaccacccggcaagctgcccgtgccctggcccacccctgaccaccctg      acctacggcggtcagtgcttcagccgtaccccgaccacatgaagcagcacgacttctcaagtccggcatgcccga      aggctacgtccaggagcgcaccatcttcaaggacgacggcaactacaagaccccgccgaggtgaagttcga      gggcgacaccctggtaaccgcattcagactgaaaggcatcgactcaaggaggacggcaacatctgggcaca      agctggagtacaactacaacagccacaacgtctatcatggccgacaaggagaacggcatcaaggtaact      caagatccgcacaacatcgaggacggcagcgtcagctgcccgaccactaccaggagaacacccccatggcg      acggcccggtcgtgtccggacaaccactacctgagcacccagtcggccctgagcaaagaccccaacgagaagg      gcgatcacatggcctgctggagttcgtgaccggccggatcacttcggcatggacgactgtacaagaagctt      agccatggctccgcggagggtggaggaggcaggatgtggcacgctgcccattgtgtgcccaggagagcggg      atggaccgtcaccctgcagcctgtgctctgtaggtcaatgttaggtcgacaaaaaaaacaaaaacaaacggcta      ttatgcgttacccgcggagacgctacggactaaataattgagcctaaagaagaattcttaagtggatgctctcaact      cagggaaacctaaatctagttatagacaaggcaatcctgagccaagccagaagtagtaattagtaagaccagtggaca      atcgaacggataacagcatatctag</p>
Circular OVA (257-264; SIINFEKL)- luciferase RNA templete	<p>taatacgcactcaactatagggggagaccctcgaccgtcgattgtccactggtaacaataatgtacttacaactatcg      aaggtgcagagactcgacggagctaccctaactgtcaagacgaggtaaagagagagactcaattctaaagccaaat      aggcagttagcgaagactgtcaagagaatgaaaatccgtgaccctaaacggctgtgtgggtcaagtccctccacccc      cacgcccggaaacgcaatagccgaaaaacaaaaacaaaaacaaaaaaaacaaaaaaaacaaaaacaaacacatct      agattaaaaacagcctgtgggtgatcccaccacaggccattggcgctagcactctgttatcacggtagctttgtgc      gcctgtttatacccccccccaactgttaacttagtaacacacaccgtcaacagtcagcgtggcacaccagcc      acgtttgatcaagcactctgttaccccgactgagttcaatagactgctcacgcggttgaaggagaaagcgttcgtt      atccggccaactacttcgaaaaacctagtaacaccgtggaagttgcagagtgttcgctcagactaccctactgttag      atcaggtcgatgatgcaccgcattccccacggcgaccgtggcggtgcgttgcggcgttgcgttgcgttgc      acccatggacgcgttaatacagacatggcgaagagacttattgagtttttttttttttttttttttttttttttttttt      gctaatcctaactgcggagcacacaccctcaagccagagggcagttgtcgtaacggcaactctgcagcggaaacc      gactacttt      ggattggccatccggactaatagacttattatcccttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc      attacaatttcattgttaagtgttaatacagcaaaatgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc      ggaccagtggggatccaccggcatggaaagacgccaacataaagaaaggccggccattctatccgttgcgttgc</p>





templete	cctgtttatgtcccttcctaactgtaaacttagaagtaacgcacacccgatcaacaggtaacgcgtggcacaccagecat gtttgtatcaaggacttctgttaccccgaccgaggatcaacagactgctacgcggtaaggagaagtgtcgat ccggccaactacttcgaaaaaccttagtaacaccatggaagtgcaagtgcttcgcactacccactgttagat caggtecatgaggatcaccgcacccccacggcgaccgtggcggtgcgtggcgcctgcataatggggaaac ccataggacgctctaatacagacatggtgcgaagagtccattgagcttagttgtagtcctccggccctgaatgcgg taatcctaactcgaggacacacccatcaagccagagggcagtgtcgtaacggcaactctgcagcggaccga ctactttgggtgtccgtttcatatttatactggctgettatggtagacaattgagagatttaccatatactattgg attggccatccatgtactcgagacttataccttttgtggttataccacctaattgaaagaagtaaaacatt agaattcattattaaattgaataca
EV29 IRES templete	ttaaaacagcctgtgggtgatcccacccacaggcccactggcgctagcactctggatcacggaccccttgcg cctgtttatacttcctccccactgcaacttagaagtaacacaaaccgatcaacaggtaacgcgtggcacaccagccac gtttgtatcaacacacttcgttaccccgactgaggatcaatagactgctacgcggtaaggagaacgttcgttat ccggccaactacttcgagaaaccttagtaacgccatggaagttggagtgttcgcctcagcactacccactgttagat cagggtatgaggatcaccgcattccccacgggtgaccgtggcggtgcgtggcgccatggggaaacc catgggacgcttatacagacatggtgcgaagagtctattgagcttagttgtagtcctccggccctgaatgcggcta atccaaactcgaggacataactctcaagccagagggtagtgcgtatggcaactctgcagcggaccgacta ctttgggtgtccgtttcatatttcatactggctttaggtgacaattgagagatttaccatatactttggatt ggccatccgtgactaacagagcttatacttttgtggttataccacttagctgaaagaggtaaaactctaca ttacatttaatactgaacaccgcaaa
VCIP IRES templete	gacctcgtaaaactgtcagaaaacaaacccaggcgatcacagcagccgcggcagcagcaccaac agcaggaggaggcaggaggaggccggaggaggaggaggaggaggcaagtttagagttgggtggcgctcc ggagttgctggctcagcgcagctccattattaaggaaaccagctgcggaggaagggtggccagcggccgcget gcccaactcgctcgactcagacgcgcgcacaacagcgcgcggcaagctgcgcagctgcataaagtttc tgctcggtatcgctcttccctggactttagaacgatttaggtgacagagggaaagcagaggcgccaggag gagcagaaaacaccacccatcgacttgcagttggaggcaggcagccggctgcactctagccgcgcggcggaggcc ggccgcggccactatccgcaggcagcgcctcgccaggaggcgaccggccctgggtgtggctgtgtgc ggacgtttcgccccggggaggctcgccgcagccagcgc
T7 promoter	TAATACGACTCACTATAAGGG
5'UTR	AAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGAGCCACC

3'UTR	GCTGCCTTCTGCAGGGCTTGCCTCTGGCCATGCCCTCTTCTCTCCCTT GCACCTGTACCTCTGGTCTTGAATAAACGCTGAGTAGGAAGT
-------	--